Retevmo (selpercatinib)

pCPA File Number: 21856

Negotiation Status:

Concluded with an LOI

Indication(s):

Metastatic RET fusion-positive non-small cell lung cancer (NSCLC), Monotherapy for the treatment of adult patients

Sponsor/Manufacturer:

Eli Lilly Canada Inc.

CDA-AMC Project Number:

PC0261-000

pCPA Engagement Letter Issued:

2022-11-17

Negotiation Process Concluded:

2023-03-31